Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates - Summary - MDSpire
Advertisement
Epitope Conservation of AZD5148, a Broadly Neutralizing Anti-Toxin B Monoclonal Antibody, Among Diverse and Global Contemporary Clostridioides difficile Isolates
To evaluate the conservation of the AZD5148 binding epitope on toxin B across diverse global C. difficile strains, highlighting its potential significance in treatment.
Key Findings:
The AZD5148 epitope is highly conserved across all geographic regions and sequence types with a conservation frequency of 99.58%, suggesting broad applicability.
Compared to bezlotoxumab, which has a conservation frequency of 82.47%, AZD5148 shows superior conservation, indicating a potentially more effective treatment.
AZD5148 demonstrated broad neutralization in vitro against 8 recently circulating ribotypes, reinforcing its therapeutic promise.
Interpretation:
The high conservation of the AZD5148 epitope suggests it is unlikely to be affected by most genotypic variations in circulating C. difficile strains, making it a promising candidate for preventing CDI recurrence and improving patient outcomes.
Limitations:
The study is based on genomic data and in vitro assays, which may not fully represent in vivo efficacy; further clinical studies are needed.
Potential variations in clinical isolates not included in the genomic dataset could affect the generalizability of findings, necessitating caution in interpretation.
Conclusion:
AZD5148 is a promising monoclonal antibody for the prevention of C. difficile infection recurrence due to its highly conserved binding epitope, positioning it as a valuable option among current treatments.
by Kelly Ann Mahool, Emily Nguyen, Victoria Godfrey, Ann Marie Stanley, Tyler Brady, Adam Gamson, Kim Rosenthal, Justin Green, Ondrej Podlaha, Bret R Sellman, Christine Tkaczyk, Vancheswaran Gopalakrishnan
